Invasive Aspergillosis Clinical Trial
Official title:
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients
Hypothesis: A pharmacogenetic score integrating both CYP3A genotypes could be influence
initial trough voriconazole plasma concentrations and thus useful to adapt a priori
voriconazole dosing in order to get adequate voriconazole exposure as possible after starting
treatment.
Main Objective: To determine predictive value of a combined pharmacogenetic score on onset of
trough voriconazole plasma concentration inferior than lower therapeutic target.
Voriconazole (VRC), the gold-standard treatment of invasive aspergillosis is characterized by
variables and nonlinear pharmacokinetics, causing many under- or over-dosing. A link exist
between trough plasma concentrations (Cmin) of VRC and effectiveness but also its toxicity.
Thus the longitudinal therapeutic drug monitoring of VRC is now recommended with a
therapeutic range between 1 and 5 mg/L. The pharmacokinetic variability of VRC is in part
explained by its metabolism, mainly dependent on cytochrome P 450 (CYP), particularly
CYP2C19, 3A4, 3A5; all these CYP exhibiting genetic polymorphisms. The authors, recently
shown, and for the first time , in a retrospective study conducted in 29 patients allogeneic
hematopoietic stem cell that initial VRC Cmin adjusted the dose was not only influenced by
the route of administration but also by a pharmacogenetics score whose determination is to
assign each genotype CYP2C19 and CYP3A a score expressed in a arbitrary units.
The combined pharmacogenetic score was strongly correlated with the original Cmin (r= -0.748;
p = 0.002) and was the only independent predictor of initial Cmin (after adjusting the dose
and the route of administration). In addition, none of the patients having a genetic score <2
(ie metabolizing capacity of reduced VRC) did not show an initial Cmin below 1 mg/L, while
the initial Cmin was below this threshold efficiency in 47% of patients with a genetic score
>2. The aim of this new study is to confirm the impact of the pharmacogenetic score on the
initial VRC Cmin over a larger prospective cohort of 60 adult patients with
onco-hematological diseases.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06028451 -
ManagemEnt of Antifungal Drug in Invasive Aspergillosis:a Real-word Study
|
||
Completed |
NCT00163722 -
A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients
|
Phase 3 | |
Completed |
NCT02394483 -
Single Ascending Oral Dose Study of F901318
|
Phase 1 | |
Completed |
NCT01128907 -
Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients
|
N/A | |
Completed |
NCT00404092 -
Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
|
Phase 2 | |
Recruiting |
NCT01386437 -
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
|
||
Withdrawn |
NCT02912026 -
Radiolabelled IV and Oral Metabolism Study of F901318
|
Phase 1 | |
Withdrawn |
NCT03095547 -
Drug/Drug Interactions With F901318
|
Phase 1 | |
Withdrawn |
NCT03076905 -
Pharmacokinetics of IV Formulation
|
Phase 1 | |
Completed |
NCT02737371 -
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
|
Phase 1 | |
Terminated |
NCT00836875 -
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
|
Phase 3 | |
Active, not recruiting |
NCT00838643 -
Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
N/A | |
Terminated |
NCT04876716 -
Azole-echinocandin Combination Therapy for Invasive Aspergillosis
|
Phase 3 | |
Recruiting |
NCT05101187 -
Olorofim Aspergillus Infection Study
|
Phase 3 | |
Enrolling by invitation |
NCT02104479 -
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
|
||
Not yet recruiting |
NCT05707832 -
A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus
|
Phase 3 | |
Recruiting |
NCT06382922 -
Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
|
||
Terminated |
NCT02396225 -
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration
|
N/A | |
Recruiting |
NCT00843804 -
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
|
N/A | |
Completed |
NCT00334412 -
COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis
|
Phase 4 |